The global schizophrenia drugs market is growing at a modest CAGR of around 2.7% during the forecast period (2019-2025). Schizoaffective disorder is a chronic mental health disorder that involves symptoms of both schizophrenia and mood disorders such as bipolar disorder or MDD. There are few drugs available in the market that are used for the treatment of both anxiety and schizophrenia. The atypical antipsychotics drugs are particularly used in the treatment of schizophrenia and bipolar disorder. Zeldox (ziprasidone) ZELDOX is used for the treatment of symptoms of schizophrenia and associated psychotic disorders, and symptoms of mixed episodes or acute manic linked with bipolar disorder. Cambridge Enterprise Ltd. is quantifying biomarkers for diagnosing and treating schizophrenia, bipolar disorder or major depression.

There are several pivotal factors that are driving the global schizophrenia drugs market, which includes growing insurance claims for mental health and government support to cater the growing mental disorders. Claims related to depression, anxiety, and other mental conditions are on the rise. Several countries have started including mental illness into medical claims including the US, UK, and India. According to the FAIR Health report, mental health-related claims are growing at a substantial rate where the claim was 1.8% of all medical claims in 2012 and it grew to 2.7% in 2017 which was an approximate 50% increase in claims in just 6 years. Further, claims for mental health rose among young individuals, which is a categorized age of less than 22. Additionally, young people accounted for an increasing share of the claims for MDD as per the report. The young individuals accounted for 15% of all claims bound to serious depression in 2007 and increased to 23% in 2017. 

Segmental Outlook  

The schizophrenia drugs market is classified on the basis of therapeutic class and treatment. Based on therapeutic class, the market is segmented into second-generation antipsychotics, third-generation antipsychotics, and other therapeutic class. Among these therapeutic class, the second-generation antipsychotics are majorly used in therapeutic classes for the treatment of schizophrenia. Based on treatment, the market is bifurcated into oral and injectables.

Global Schizophrenia Drugs Market Share by Treatment, 2018(%)

Regional Outlook 

The global schizophrenia drugs market is classified on the basis of geography, which includes North America, Europe, Asia-Pacific, and Rest of the World. North America contributes a significant share in the schizophrenia drugs market. An increased level of stress has been reported in the US. As per the several studies conducted by the American Institute of Stress (AIS), it was demonstrated that job stress is the major source of stress among American adults, which has intensified over the last decades. As per the report of the National Alliance on Mental Illness, nearly 1.2% of US adults experience OCD every year. In the overall prevalence of OCD among adults, women are more prone to be affected by OCD in comparison to men. In addition, the increasing incidence of anxiety disorders in North America is generating the demand for different types of medication and therapies for its treatment and thereby is expected to propel the growth of the schizophrenia drugs market in the region.

Global Schizophrenia Drugs Market Growth, by Region 2019-2025

Asia-Pacific is expected to propel with a considerable growth rate in the global market

Asia-Pacific is estimated to project a considerable CAGR in the global schizophrenia drugs market. Countries in Asia-Pacific that are contributing to the market growth include China, India, and Japan. The market in the region is largely driven by the significant prevalence of behavioral health disorders such as depression, anxiety, the stress in the country coupled with initiatives and programs for stress management. According to the World Health Organization (WHO), a total 54 million people in China suffered from depression and 41 million people suffered from anxiety disorders in 2017. Furthermore, as per the Healthy China 2019-2030 targets, at least 30% of patients suffering from depression are to access treatment by 2022 and around 80% by 2030. Along with China, as per Otsuka Pharmaceuticals, Inc., in 2015, there are approximately 710,000 people with schizophrenia in Japan due to which the demand for drugs for schizophrenia has been growing considerably in the country, which in turn, is driving the growth of the schizophrenia drugs market in Japan.

Market Players Outlook

The key players in the schizophrenia drugs market are contributing significantly by providing advanced technology-based products and through expanding their geographical presence across the globe. The key players operating in the global schizophrenia drugs market include Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. These market players adopt various strategies such as product launch, partnerships, collaborations, merger, and acquisitions to sustain a strong position in the market. For instance, in September 2019, Catalent, Inc. and Minerva Neurosciences, Inc. entered into a long-term commercial supply agreement for roluperidone (MIN-101), an investigational compound under development by Minerva, for the treatment of negative symptoms of schizophrenia.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global schizophrenia drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.